Societe Generale’s Acadia Pharmaceuticals ACAD Stock Holding History

Societe Generale’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$406K	Buy	+12,502	New	+$418K	﹤0.01%	1820

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Societe Generale's ACAD Position: Q2 2016 in Review

Societe Generale opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2016: 12,502 shares worth $406K. The stake represents ﹤0.01% of the portfolio and ranks #1820 among its holdings.

227 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

Societe Generale held 12,502 shares of Acadia Pharmaceuticals worth $406K as of Q2 2016.
Acadia Pharmaceuticals was a new Societe Generale position in Q2 2016.
Acadia Pharmaceuticals made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1820 holding.
227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.